VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Valneva SE
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 20-F on Mar 17, 2026
$5.51−0.10 (-1.78%)
Close on Oct 19, 2026
Share price
−$4.53 (−45.12%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Valneva SE grew revenue 3.0% to €174.66M over the twelve months to Dec 31, 2025. Operating income fell 715.6% to -€82.06M, moving the operating margin from 7.9% to -47.0%. Free cash flow was -€57.31M.
Revenue
€174.66M
+3.0% vs. a year earlier
Operating income
-€82.06M
-715.6% vs. a year earlier
Free cash flow
-€57.31M
TTM Q4 2025
EPS, diluted
-0.68 EUR
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- €174.66M
- EPS, diluted
- -0.68 EUR
- Free cash flow
- -€57.31M
Valuation needs the share price. It fills in once daily prices are connected and converted from EUR.
Seven years at a glance
Fiscal years 2019 to 2025, EUR
Revenue
€174.66M+3.0% YoY
Gross profit
€67.52M-5.0% YoY
Operating income
-€82.06M-715.6% YoY
Net income
–
EPS, diluted
-0.68 EUR
Free cash flow
-€57.31M
Reported period